Martha Rodríguez-Morán1, Fernando Guerrero-Romero. 1. Medical Research Unit in Clinical Epidemiology of the Mexican Social Security Institute, Durango, Mexico. rodriguez_moran@hotmail.com
Abstract
OBJECTIVE: To determine whether oral magnesium supplementation (as magnesium chloride [MgCl(2)] solution) improves both insulin sensitivity and metabolic control in type 2 diabetic subjects with decreased serum magnesium levels. RESEARCH DESIGN AND METHODS: This study was a clinical randomized double-blind placebo-controlled trial. A total of 63 subjects with type 2 diabetes and decreased serum magnesium (serum magnesium levels </=0.74 mmol/l) treated byglibenclamide received either 50 ml MgCl(2) solution (containing 50 g MgCl(2) per 1,000 ml solution) or placebo daily for 16 weeks. Chronic diarrhea, alcoholism, use of diuretic and/or calcium antagonist drugs, and reduced renal function were exclusion criteria. Homeostasis model assessment for insulin resistance (HOMA-IR) was used as the parameter of insulin sensitivity and glucose and HbA(1c) as parameters of metabolic control. RESULTS: At the end of the study, subjects who received magnesium supplementation showed significant higher serum magnesium concentration (0.74 +/- 0.10 vs. 0.65 +/- 0.07 mmol/l, P = 0.02) and lower HOMA-IR index (3.8 +/- 1.1 vs. 5.0 +/- 1.3, P = 0.005), fasting glucose levels (8.0 +/- 2.4 vs. 10.3 +/- 2.1 mmol/l, P = 0.01), and HbA(1c) (8.0 +/- 2.4 vs. 10.1 +/- 3.3%, P = 0.04) than control subjects. CONCLUSIONS: Oral supplementation with MgCl(2) solution restores serum magnesium levels, improving insulin sensitivity and metabolic control in type 2 diabetic patients with decreased serum magnesium levels.
RCT Entities:
OBJECTIVE: To determine whether oral magnesium supplementation (as magnesium chloride [MgCl(2)] solution) improves both insulin sensitivity and metabolic control in type 2 diabetic subjects with decreased serum magnesium levels. RESEARCH DESIGN AND METHODS: This study was a clinical randomized double-blind placebo-controlled trial. A total of 63 subjects with type 2 diabetes and decreased serum magnesium (serum magnesium levels </=0.74 mmol/l) treated by glibenclamide received either 50 ml MgCl(2) solution (containing 50 g MgCl(2) per 1,000 ml solution) or placebo daily for 16 weeks. Chronic diarrhea, alcoholism, use of diuretic and/or calcium antagonist drugs, and reduced renal function were exclusion criteria. Homeostasis model assessment for insulin resistance (HOMA-IR) was used as the parameter of insulin sensitivity and glucose and HbA(1c) as parameters of metabolic control. RESULTS: At the end of the study, subjects who received magnesium supplementation showed significant higher serum magnesium concentration (0.74 +/- 0.10 vs. 0.65 +/- 0.07 mmol/l, P = 0.02) and lower HOMA-IR index (3.8 +/- 1.1 vs. 5.0 +/- 1.3, P = 0.005), fasting glucose levels (8.0 +/- 2.4 vs. 10.3 +/- 2.1 mmol/l, P = 0.01), and HbA(1c) (8.0 +/- 2.4 vs. 10.1 +/- 3.3%, P = 0.04) than control subjects. CONCLUSIONS: Oral supplementation with MgCl(2) solution restores serum magnesium levels, improving insulin sensitivity and metabolic control in type 2 diabeticpatients with decreased serum magnesium levels.
Authors: Leo A Celi; Daniel J Scott; Joon Lee; Rachel Nelson; Seth L Alper; Kenneth J Mukamal; Roger G Mark; John Danziger Journal: J Hypertens Date: 2013-11 Impact factor: 4.844
Authors: Rebecca B Costello; Ronald J Elin; Andrea Rosanoff; Taylor C Wallace; Fernando Guerrero-Romero; Adela Hruby; Pamela L Lutsey; Forrest H Nielsen; Martha Rodriguez-Moran; Yiqing Song; Linda V Van Horn Journal: Adv Nutr Date: 2016-11-15 Impact factor: 8.701
Authors: Daniel T Dibaba; Pengcheng Xun; Yiqing Song; Andrea Rosanoff; Michael Shechter; Ka He Journal: Am J Clin Nutr Date: 2017-07-19 Impact factor: 7.045